Prostate cancer High-dose-rate brachytherapy Recurrent disease
Conditions
Interventions
Single fraction focal high-dose-rate brachytherapy to a dose of 19 Gray
Sponsors
University Medical Center Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: - Age >18 years; - Recurrence >2 years after primary radiotherapy treatment (LDR-BT or EBRT); - PSA at time of salvage 9 months; - Maximum stage T3b tumor (extra prostatic extension into the seminal vesicle(s)); - Acceptable toxicity of primary radiation treatment (IPSS 70 - Written informed consent; - Fit for spinal anesthesia.
Exclusion criteria
Exclusion criteria: - Distant metastases; - Previous pelvic radiotherapy for another malignancy; - Prior prostate treatment(s) like a recent transurethral resection of the prostate (TURP) (15); - Anticoagulant administration continuously required, except for platelet aggregation inhibitors (for example Ascal/Persantin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the occurrence of acute and late (>3 months) grade >2 GI and/or GU toxicity (aiming for 2 toxicity) after MRI-guided focal salvage HDR-BT for locally recurrent prostate cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| - QoL; - Biochemical disease free survival; - Assessment of dose restrictions to prevent/reduce acute and late GU/GI toxicity; - Predictive factors for tumor control, to optimize patient selection. | — |
Contacts
Public ContactJ.R.N. Voort van Zyp, van der
UMC Utrecht, Department of Radiotherapy
Outcome results
None listed